Breaking News Instant updates and real-time market news.

GSK

GlaxoSmithKline

$42.34

0.3 (0.71%)

, MRK

Merck

$82.92

-0.95 (-1.13%)

14:41
09/29/19
09/29
14:41
09/29/19
14:41

GlaxoSmithKline presents new data showing anti-tumor activity with GSK3359609

GlaxoSmithKline (GSK) announced GSK3359609, an inducible T cell co-stimulatory agonist antibody designed to selectively enhance T cell function, showed anti-tumor activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcinoma. Findings from the INDUCE-1 study also suggested GSK3359609 has single agent activity in patients with PD-1/L1 experienced HNSCC. The safety and tolerability profile of GSK3359609 was consistent with the results reported in the dose escalation phase of INDUCE-1. The data presented stem from the expansion phase of INDUCE-1, a first-in-human, open-label study investigating GSK3359609 as a monotherapy and in combination with other regimens. Patients in the study had recurrent or metastatic HNSCC and had received up to five prior lines of therapy in the advanced setting. Patients in the monotherapy cohort had previously been treated with PD-1/L1 therapy and received 1 mg/kg GSK3359609. Patients in the combination cohort were naive to PD-1/L1 therapy and received 0.3 mg/kg GSK3359609 and 200 mg pembrolizumab. Patients in both cohorts were evaluated until disease progression or unacceptable toxicity, for up to two years. In the 34 evaluable patients who received the combination therapy, the overall response rate was 24%. Responses in the combination cohort were durable with all responding patients maintaining benefit for 6 months or longer; the median progression-free survival was 5.6 months. Of the 21 patients with known PD-L1 expression data, the majority of responders and patients with stable disease had PD-L1 score below 20. Of the 16 evaluable patients who received monotherapy, the overall response rate was 6%. The INDUCE-1 study was conducted pursuant to an agreement between GSK and Merck (MRK). GSK is continuing its relationship with MSD to support the INDUCE-3 phase II/III combination trial to be initiated by the end of 2019.

GSK

GlaxoSmithKline

$42.34

0.3 (0.71%)

MRK

Merck

$82.92

-0.95 (-1.13%)

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 23

    Oct

  • 29

    Oct

  • 14

    Mar

GSK GlaxoSmithKline
$42.34

0.3 (0.71%)

08/13/19
JPMS
08/13/19
INITIATION
JPMS
Neutral
GlaxoSmithKline reinstated with a Neutral at JPMorgan
JPMorgan analyst James Gordon reinstated coverage of GlaxoSmithKline with a Neutral rating and 1,700p price target. The analyst sees the stock near-term being Brexit and currency moves.
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
GlaxoSmithKline upgraded to Buy from Sell at Societe Generale
09/03/19
SOCG
09/03/19
UPGRADE
SOCG
Buy
Societe Generale double upgrades GlaxoSmithKline to Buy
As previously reported, Societe Generale analyst Justin Smith upgraded GlaxoSmithKline to Buy from Sell in a research note titled 'An intriguing metamorphosis.' The analyst said he waited to upgrade the stock, despite liking "all the management and capital allocation changes" that new CEO Emma Walmsley has made in her first two years in charge, because he wanted to see "clear evidence of improving innovation" with GlaxoSmithKline's Pharma business. Smith now sees five high profile assets in Phase 3 that will release results in the next 3-4 years, giving improved pipeline visibility, and leaving the analyst forecasting "above-average sales growth from 2023."
09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
MRK Merck
$82.92

-0.95 (-1.13%)

08/07/19
ARGS
08/07/19
NO CHANGE
Target $105
ARGS
Buy
Merck price target raised to $105 from $95 at Argus
Argus analyst David Toung raised his price target on Merck to $105 and kept his Buy rating after its "strong" Keytruda-driven Q2 earnings beat, also boosting his FY19 and FY20 EPS view by 16c and 10c to $4.89 and $5.35 respectively. The analyst sees Merck's "blockbuster" Keytruda drug on track for additional indications in the U.S., Japan, China and Europe, with additional growth drivers coming from its Gardasil, Bridion, Lynparza, and Lenvima programs.
08/15/19
LEER
08/15/19
INITIATION
Target $103
LEER
Outperform
Merck initiated with an Outperform at SVB Leerink
SVB Leerink analyst Daina Graybosch initiated Merck with an Outperform rating and $103 price target.
08/16/19
08/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Merck (MRK) initiated with an Outperform at SVB Leerink. 2. DocuSign (DOCU) initiated with a Buy at DA Davidson. 3. iQIYI (IQ) initiated with an Underweight at JPMorgan. 4. Goodyear Tire (GT) initiated with an Outperform at Exane BNP Paribas. 5. BlackBerry (BB) initiated with a Neutral at Macquarie. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/19
RHCO
09/18/19
NO CHANGE
Target $14
RHCO
Hold
Lannett price target raised to $14 from $10 at SunTrust
SunTrust analyst Gregg Gilbert raised his price target on Lannett (LCI) to $14, adjusting his model to reflect its potentially significant opportunity with the recent launch of posaconazole - a generic version of Merck's (MRK) Noxafil. The analyst notes that he now models sales and EBITDA at the higher end of the company's FY20 targets while also raising his FY20 EPS view by 19c to $1.33. Gilbert still keeps his Hold rating on the stock, citing the uncertainty around Lannett's capital structure and limited pipeline visibility as well as the challenging environment for generics.

TODAY'S FREE FLY STORIES

CBU

Community Bank System

$63.64

0.58 (0.92%)

06:54
10/21/19
10/21
06:54
10/21/19
06:54
Earnings
Community Bank System reports Q3 operating EPS 84c, consensus 81c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

MDT

Medtronic

$108.18

-0.365 (-0.34%)

06:53
10/21/19
10/21
06:53
10/21/19
06:53
Hot Stocks
Medtronic names Sean Salmon as EVP, Group President of Medtronic Diabetes »

Medtronic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BMRN

BioMarin

$69.16

1.27 (1.87%)

06:53
10/21/19
10/21
06:53
10/21/19
06:53
Recommendations
BioMarin analyst commentary  »

Cantor sees successful…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 07

    Dec

KMT

Kennametal

$30.73

0.9 (3.02%)

06:53
10/21/19
10/21
06:53
10/21/19
06:53
Earnings
Kennametal cuts FY20 adj. EPS view to $1.70-$2.10 from $2.80-$3.20 

Consensus $2.81.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 14

    Nov

KMT

Kennametal

$30.73

0.9 (3.02%)

06:52
10/21/19
10/21
06:52
10/21/19
06:52
Hot Stocks
Kennametal CEO says Q1 results are well below expectations »

"Our first quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 14

    Nov

CFWFF

Calfrac Well Services

$0.00

(0.00%)

06:50
10/21/19
10/21
06:50
10/21/19
06:50
Downgrade
Calfrac Well Services rating change  »

Calfrac Well Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$18.44

-0.07 (-0.38%)

06:50
10/21/19
10/21
06:50
10/21/19
06:50
Hot Stocks
Halliburton CEO says 'our organization executed effectively' in Q3 »

"Our organization…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

PTON

Peloton

$23.44

-0.41 (-1.72%)

, BABA

Alibaba

$169.18

-7.665 (-4.33%)

06:49
10/21/19
10/21
06:49
10/21/19
06:49
Recommendations
Peloton, Alibaba analyst commentary  »

Stifel adds Peloton to…

PTON

Peloton

$23.44

-0.41 (-1.72%)

BABA

Alibaba

$169.18

-7.665 (-4.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 19

    Nov

KMT

Kennametal

$30.73

0.9 (3.02%)

06:48
10/21/19
10/21
06:48
10/21/19
06:48
Earnings
Kennametal reports preliminary Q1 adj. EPS 17c, consensus 49c »

Reports preliminary Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 14

    Nov

CBU

Community Bank System

$63.64

0.58 (0.92%)

06:48
10/21/19
10/21
06:48
10/21/19
06:48
Hot Stocks
Community Bank System acquires Steuben Trust for $106.8M »

Community Bank System and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

SGEN

Seattle Genetics

$87.42

1.48 (1.72%)

06:48
10/21/19
10/21
06:48
10/21/19
06:48
Hot Stocks
Seattle Genetics says HER2CLIMB trial met primary endpoint »

Seattle Genetics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 07

    Dec

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:47
10/21/19
10/21
06:47
10/21/19
06:47
Initiation
Peloton initiated  »

Peloton initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PINS

Pinterest

$25.30

-0.7 (-2.69%)

06:46
10/21/19
10/21
06:46
10/21/19
06:46
Upgrade
Pinterest rating change  »

Pinterest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 19

    Nov

HAL

Halliburton

$18.44

-0.07 (-0.38%)

06:45
10/21/19
10/21
06:45
10/21/19
06:45
Earnings
Halliburton reports Q3 EPS 34c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

CMG

Chipotle

$841.97

13.88 (1.68%)

06:42
10/21/19
10/21
06:42
10/21/19
06:42
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 12

    Nov

PTON

Peloton

$23.44

-0.41 (-1.72%)

06:42
10/21/19
10/21
06:42
10/21/19
06:42
Initiation
Peloton initiated  »

Peloton initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

06:39
10/21/19
10/21
06:39
10/21/19
06:39
Downgrade
Credit Suisse can no longer defend Boeing shares, downgrades to Neutral »

Credit Suisse analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GIL

Gildan Activewear

$26.27

-9.105 (-25.74%)

06:36
10/21/19
10/21
06:36
10/21/19
06:36
Downgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

OPRT

Oportun Financial

$15.89

-0.22 (-1.37%)

06:36
10/21/19
10/21
06:36
10/21/19
06:36
Initiation
Oportun Financial initiated  »

Oportun Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONB

Old National Bancorp

$17.19

0.11 (0.64%)

06:35
10/21/19
10/21
06:35
10/21/19
06:35
Earnings
Old National Bancorp reports Q3 adjusted EPS 41c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 13

    Nov

GIL

Gildan Activewear

$26.27

-9.105 (-25.74%)

06:33
10/21/19
10/21
06:33
10/21/19
06:33
Upgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

KNOP

KNOT Offshore Partners

$19.50

0.02 (0.10%)

06:32
10/21/19
10/21
06:32
10/21/19
06:32
Initiation
KNOT Offshore Partners initiated  »

KNOT Offshore Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

BXBLY

Brambles

$0.00

(0.00%)

06:29
10/21/19
10/21
06:29
10/21/19
06:29
Upgrade
Brambles rating change  »

Brambles upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$114.79

-0.55 (-0.48%)

06:28
10/21/19
10/21
06:28
10/21/19
06:28
Periodicals
U.S. considers extension of Chevron's Venezuela waiver, Bloomberg says »

The U.S. is considering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

DTE

DTE Energy

$127.38

-2.11 (-1.63%)

06:26
10/21/19
10/21
06:26
10/21/19
06:26
Upgrade
DTE Energy rating change  »

DTE Energy upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.